WELL PHARMA MEDICAL RESEARCH.
New Study Call-In Information Sheet
|
Sex |
Age |
# Visits |
Payment |
Diagnosis |
# Subjects |
|
F/M |
At least 18 years |
14 |
Visit -$100(visit 4,5,6 extra $75) TC – $25 Disc $100 Unsc – $50 |
Chronic Cough |
8 |
Protocol # MK-7264-027-01
Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study
To Evaluate the Efficacy and Safety of MK-7264 in Adult Participants with Chronic Cough
(PN027)
Coordinator: Guido Elias
Type of Volunteer: Adults with Chronic Cough
Length of Study: 54 Weeks (379 Days)
Specific Inclusions:
- Chest radiograph or computed tomography scan of the thorax (within 5 years of screening Visit)
- Have chronic cough for ≥1 year and a diagnosis of refractory chronic cough or unexplained chronic cough.
- Women and men at least 18 years of age at the time of informed consent.
Specific Exclusions:
- Current smoker.
- History of upper or lower respiratory tract infection or recent clinically significant
- change in pulmonary status within 4 weeks of Screening/Visit 1
- History of chronic bronchitis, defined as a cough that produces a clinically significant amount of sputum (greater than approximately 1 tablespoon of phlegm) that occurs every day for at least 3 months in a row, with those periods occurring at least 2 years in a row.
- Individuals who are currently taking an angiotensin converting enzyme inhibitor or have taken an angiotensin converting enzyme inhibitor within 3 months of Screening/Visit 1.
- Screening systolic blood pressure >160 mm Hg or a diastolic blood pressure >90 mmHg.